GeneReach Biotechnology (ROCO:4171) Research & Development: NT$72.8 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4171 GeneReach Biotechnology Corp ROCO:4171
60 GF Score
Price NT$18.45
GF Value NT$23.98
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is GeneReach Biotechnology Research & Development?

GeneReach Biotechnology ROCO:4171 -5.87% 60 Research & Development is NT$72.8 Mil as of Dec. 2025. GuruFocus rates ROCO:4171 with a GF Score™ of 60/100 and a GF Value™ of NT$23.98 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. GeneReach Biotechnology's Research & Development for the three months ended in Dec. 2025 was NT$18.8 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was NT$72.8 Mil.

GeneReach Biotechnology  (ROCO:4171) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

GeneReach Biotechnology Research & Development Related Terms

GeneReach Biotechnology Research & Development Historical Data

* Premium members only.

The historical data trend for GeneReach Biotechnology's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GeneReach Biotechnology Research & Development Chart

GeneReach Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 68.78 56.61 58.81 61.46 80.51

GeneReach Biotechnology Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 18.95 17.72 20.64 15.64 18.75
ROCO:4171
60GF Score
GeneReach Biotechnology Corp ROCO:4171
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

GeneReach Biotechnology Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$72.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of NT$72.8 Mil mean?
GeneReach Biotechnology (ROCO:4171) has a Research & Development of NT$72.8 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on GeneReach Biotechnology and its competitors.
Is GeneReach Biotechnology's Research & Development too high?
GeneReach Biotechnology's current Research & Development is NT$72.8 Mil. Overall, GeneReach Biotechnology has a GF Score™ of 60/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does GeneReach Biotechnology's Research & Development compare to VRTX and REGN?
GeneReach Biotechnology's Research & Development of NT$72.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on GeneReach Biotechnology and its competitors. GeneReach Biotechnology's current Research & Development is NT$72.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is GeneReach Biotechnology stock overvalued right now?
Based on GuruFocus' analysis, GeneReach Biotechnology (ROCO:4171) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$23.98, compared to a current price of NT$18.45 — trading 23.1% below its estimated fair value. The current Research & Development is NT$72.8 Mil. GeneReach Biotechnology's overall GF Score™ is 60/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For GeneReach Biotechnology (ROCO:4171), the current Research & Development is NT$72.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is GeneReach Biotechnology (ROCO:4171) Overvalued in 2026?

Based on GuruFocus' analysis, GeneReach Biotechnology stock appears to be undervalued. The current stock price of NT$18.45 is trading 23.1% below its estimated GF Value™ of NT$23.98. GuruFocus considers GeneReach Biotechnology to be Modestly Undervalued.

Key valuation signals for ROCO:4171:

  • Research & Development: NT$72.8 Mil
  • GF Value™: NT$23.98 vs. price of NT$18.45 (23.1% below fair value)
  • GF Score™: 60/100 with 3 warning signs

No single metric tells the full story. See the ROCO:4171 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

GeneReach Biotechnology Business Description

Address No.19, Keyuan 2nd Road, Taichung, TWN, 407
GeneReach Biotechnology Corp is a biotechnology company. The company develops, manufactures and markets products for applied nucleic acid detection technology. Its products are utilised for aquaculture, agriculture, food, companion animal, livestock and human health industries.
60GF Score

Get the complete analysis for ROCO:4171

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$18.45
Price
NT$23.98
GF Value